A detailed history of Nuveen Asset Management, LLC transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 162,304 shares of CABA stock, worth $762,828. This represents 0.0% of its overall portfolio holdings.

Number of Shares
162,304
Previous 198,037 18.04%
Holding current value
$762,828
Previous $3.38 Million 64.06%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$7.22 - $18.82 $257,992 - $672,495
-35,733 Reduced 18.04%
162,304 $1.21 Million
Q1 2024

May 13, 2024

SELL
$16.79 - $25.38 $734,562 - $1.11 Million
-43,750 Reduced 18.09%
198,037 $3.38 Million
Q4 2023

Feb 14, 2024

BUY
$12.21 - $23.36 $1.29 Million - $2.47 Million
105,809 Added 77.81%
241,787 $5.49 Million
Q3 2023

Nov 14, 2023

BUY
$11.84 - $18.65 $638,294 - $1.01 Million
53,910 Added 65.69%
135,978 $2.07 Million
Q2 2023

Aug 14, 2023

BUY
$7.65 - $13.95 $627,820 - $1.14 Million
82,068 New
82,068 $1.06 Million
Q2 2021

Aug 16, 2021

SELL
$7.2 - $11.73 $492,487 - $802,343
-68,401 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$10.39 - $14.53 $613 - $857
59 Added 0.09%
68,401 $759,000
Q4 2020

Feb 16, 2021

BUY
$9.81 - $15.8 $2,099 - $3,381
214 Added 0.31%
68,342 $853,000
Q3 2020

Nov 16, 2020

BUY
$9.71 - $14.41 $220,494 - $327,222
22,708 Added 50.0%
68,128 $738,000
Q2 2020

Aug 14, 2020

BUY
$6.39 - $11.28 $184,472 - $325,642
28,869 Added 174.42%
45,420 $506,000
Q1 2020

May 14, 2020

BUY
$6.0 - $18.67 $37,164 - $115,641
6,194 Added 59.8%
16,551 $120,000
Q4 2019

Feb 14, 2020

BUY
$7.88 - $17.71 $81,613 - $183,422
10,357 New
10,357 $145,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $136M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.